IP Library Granted Patent US 7,544,478
Granted Patent B2
US 7,544,478 · App. 10/914,669 · Granted Jun 9, 2009

Method for screening for compounds that modulate P16 mediated regulation of NMDA receptors

Assignee: The Burnham Institute
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,544,478
App. No.
10/914,669
Granted
Jun 9, 2009
Kind
B2
Abstract

Discovered is a novel protein and variants thereof whose activity at the NMDA receptor causes an increased efflux of calcium ions through the channel of said receptor. This activity is downregulated by the NR3A subunit of NMDA. Also discovered are the nucleic acid sequences encoding said novel protein and variants thereof. The discovery is useful for the diagnosing of NMDA receptor dysregulation and the treatment of NMDA receptor dysregulation related disorders. In addition, the discovery is useful for the further discovery of modulators affecting the activity of the novel protein and variants thereof at the NMDA receptor.

Claims (12)

1. A method for screening compounds that modulate p16 activity, comprising:

(a) providing an in vitro format having an NMDA receptor that is detectably capable of cation efflux;

(b) providing at least one amino acid sequence comprising at least 95% identity to SEQ ID NO: 3 (p16);

(c) introducing a candidate compound; and

(d) selecting those compounds that modulate cation efflux activity of the NMDA receptor,

wherein the in vitro format that provides the NMDA receptor that is detectably capable of cation efflux is a human cell.

2. The method of claim 1 wherein the NMDA receptor comprises all subunits.

3. The method of claim 1 wherein the NR3A subunit is knocked out.

4. The method of claim 1 wherein said compound is selected from the group consisting of a peptide, polypeptide, peptidomimetic, an antibody or antibody fragment, siRNA, anti-sense RNA, gene therapy products and a nucleotide sequence.

5. The method of claim 4 wherein said compound increases cation efflux activity of the NMDA receptor.

6. The method of claim 4 wherein said compound decreases cation efflux activity of the NMDA receptor.

7. The method of claim 1 , wherein the format that provides the NMDA receptor that is detectably capable of cation efflux is a neuronal cell selected from the group consisting of amygdala cells, hippocampus cells and cerebral cortex cells.

Assignments (5)
CONFIRMATORY LICENSE Recorded May 10, 2023
From: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
To: NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR
Reel/Frame 063600/0850 →
CONFIRMATORY LICENSE Recorded Jul 21, 2022
From: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
To: NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR
Reel/Frame 060575/0309 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 28, 2006
From: TONG, GANG
To: THE BURNHAM INSTITUTE FOR MEDICAL RESEARCH
Reel/Frame 018557/0512 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 28, 2006
From: NAKANISHI, NOBUKI
To: THE BURNHAM INSTITUTE FOR MEDICAL RESEARCH
Reel/Frame 018557/0620 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 28, 2006
From: TU, SHICHUN
To: THE BURNHAM INSTITUTE FOR MEDICAL RESEARCH
Reel/Frame 018557/0636 →
Continuity (2)
Provisional Application 6049401700 · Aug 8, 2003
Related Publication 20050037433A1 · Feb 17, 2005